摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-2-氟-6-甲基吡啶 | 375368-83-5

中文名称
5-溴-2-氟-6-甲基吡啶
中文别名
2-甲基-3-溴-6-氟吡啶;3-溴-2-甲基-6-氟吡啶;2-氟-5-溴-6-甲基吡啶
英文名称
3-bromo-6-fluoro-2-methylpyridine
英文别名
——
5-溴-2-氟-6-甲基吡啶化学式
CAS
375368-83-5
化学式
C6H5BrFN
mdl
MFCD03095092
分子量
190.015
InChiKey
GUYGQQWIKZLHTP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    189.5±35.0 °C(Predicted)
  • 密度:
    1.592±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S39
  • 危险类别码:
    R22,R37/38,R41
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:fca7dd1cc49a1210d7618d8629af6298
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Bromo-6-fluoro-2-methylpyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-6-fluoro-2-methylpyridine
CAS number: 375368-83-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5BrFN
Molecular weight: 190.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-溴-2-氟-6-甲基吡啶chromium(VI) oxide硫酸 作用下, 反应 18.0h, 以58%的产率得到3-溴-6-氟吡啶甲酸
    参考文献:
    名称:
    多取代的6-氟皮考啉酸的制备方法
    摘要:
    本发明公开了一种多取代的6‑氟皮考啉酸的制备方法,包括:将多取代的2‑氨基‑6‑甲基吡啶与重氮化试剂进行重氮化后,再与氟化剂进行反应,生成多取代的2‑氨基‑6‑氟吡啶;将多取代的6‑甲基‑2‑氟吡啶与氧化剂进行氧化反应,得到多取代的6‑氟皮考啉酸。本发明提供了一种制备多取代的6‑氟皮考啉酸的新的起始原料并相应地提供了一种新的反应路径和工艺。以多取代的2‑氨基‑6‑甲基吡啶作为起始原料成本低,易获得,本发明制备多取代的6‑氟皮考啉酸的工艺简单,反应条件要求低,安全性能好,产品收率和纯度高并且容易实现规模化生产。
    公开号:
    CN108341769A
  • 作为产物:
    描述:
    2-氨基-5-溴-6-甲基吡啶potassium nitrite氟化氢吡啶 作用下, 反应 4.0h, 以78%的产率得到5-溴-2-氟-6-甲基吡啶
    参考文献:
    名称:
    多取代的6-氟皮考啉酸的制备方法
    摘要:
    本发明公开了一种多取代的6‑氟皮考啉酸的制备方法,包括:将多取代的2‑氨基‑6‑甲基吡啶与重氮化试剂进行重氮化后,再与氟化剂进行反应,生成多取代的2‑氨基‑6‑氟吡啶;将多取代的6‑甲基‑2‑氟吡啶与氧化剂进行氧化反应,得到多取代的6‑氟皮考啉酸。本发明提供了一种制备多取代的6‑氟皮考啉酸的新的起始原料并相应地提供了一种新的反应路径和工艺。以多取代的2‑氨基‑6‑甲基吡啶作为起始原料成本低,易获得,本发明制备多取代的6‑氟皮考啉酸的工艺简单,反应条件要求低,安全性能好,产品收率和纯度高并且容易实现规模化生产。
    公开号:
    CN108341769A
点击查看最新优质反应信息

文献信息

  • Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization
    作者:Tsuyoshi Shinozuka、Tomoharu Tsukada、Kunihiko Fujii、Eri Tokumaru、Kousei Shimada、Yoshiyuki Onishi、Yumi Matsui、Satoko Wakimoto、Masanori Kuroha、Tsuneaki Ogata、Kazushi Araki、Jun Ohsumi、Ryoko Sawamura、Nobuaki Watanabe、Hideki Yamamoto、Kazunori Fujimoto、Yoshiro Tani、Makoto Mori、Jun Tanaka
    DOI:10.1016/j.bmc.2018.09.005
    日期:2018.10
    synthesized compound (II) for the avoidance of hepatotoxicity. The replacement of the left-hand side benzene with 2-pyridine resulted in the substantial loss of potency. Because poor membrane permeability was responsible for poor potency in vitro, the adjustment of lipophilicity was examined, which resulted in the discovery of dimethyl pyridine derivative (I, DS-6930). In preclinical studies, DS-6930 demonstrated
    为了避免肝毒性,尝试降低先前合成的化合物(II)的亲脂性。用2-吡啶代替左手侧苯导致效力的实质损失。由于差的膜通透性导致体外效价差,因此对亲脂性的调节进行了检查,从而发现了二甲基吡啶衍生物(I,DS-6930)。在临床前研究中,DS-6930表现出较高的PPARγ激动剂效价,且血浆葡萄糖降低明显。DS-6930在体内进行毒理学评估后维持与PPARγ相关的副作用减少,并没有显示出肝毒性。辅助因子募集测定表明,显着募集了一些辅助因子,例如RIP140和PGC1,而几个典型因子并未受到影响。这种选择性辅因子募集是由于DS-6930的独特结合模式引起的。钙盐DS-6930b被认为是有效的胰岛素增敏剂,无水肿,可在T2DM患者中进行临床评估。
  • [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES SUBSTITUÉS ANTIDIABÉTIQUES
    申请人:MERCK SHARP & DOHME
    公开号:WO2015089809A1
    公开(公告)日:2015-06-25
    The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    本发明涉及一种由公式I表示的化合物:以及它们的药用可接受盐。公式I的化合物是G蛋白偶联受体40(GPR40)的激动剂,可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病,以及通常与该疾病相关的状况,包括肥胖和脂质紊乱,如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。
  • [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
    申请人:MERCK SHARP & DOHME
    公开号:WO2015095256A1
    公开(公告)日:2015-06-25
    The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    本发明涉及一种由公式(I)表示的化合物:以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40(GPR40)的激动剂,并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病,以及通常与该疾病相关的状况,包括肥胖和脂质紊乱,如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
  • [EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012168350A1
    公开(公告)日:2012-12-13
    The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    本发明涉及式(I)的化合物,其中R1至R4的定义如描述和权利要求中所述。式(I)的化合物可以用作药物。
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    申请人:CHAN Ho Man
    公开号:US20160176882A1
    公开(公告)日:2016-06-23
    A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein.
    提供了一种由化合物(I)或其药学上可接受的盐组成的药物,已被证明对治疗PRC2介导的疾病或紊乱有用:其中R1、R2、R3、R4、R5和n的定义如本文所述。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-